POP-OUT | CLOSE
 
 
4-AMINO-1-HYDROXYBUTANE-1,1-DIYLDIPHOSPHONATE
 
AHD is found in 4 entries
AHD
  •   Chemical Component Summary   Hide
    Name 4-AMINO-1-HYDROXYBUTANE-1,1-DIYLDIPHOSPHONATE
    Identifiers (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonate)
    4-azanyl-1,1-diphosphonato-butan-1-ol
    Synonyms ALENDRONATE, FOSAMAX (TM)
    Formula C4 H9 N O7 P2
    Molecular Weight 245.06 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key OGSPWJRAVKPPFI-UHFFFAOYSA-J
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00630   (Different stereochemistry)
    Name Alendronate
    Groups approved
    Description Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Paget’s disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Paget’s disease.
    Synonyms
    • Acide Alendronique [INN-French]
    • Acido Alendronico [INN-Spanish]
    • Acidum Alendronicum [INN-Latin]
    • Alendronate Sodium
    • Alendronic acid
    Brand names
    • Adronat
    • Alendros
    • Arendal
    • Fosamax
    • Fosamax Plus D
    • Onclast
    [more]
    Affected organism Humans and other mammals
    Indication For the treatment and prevention of osteoporosis in women and Paget's disease of bone in both men and women.
    Pharmacology Alendronate, a second-generation bisphosphonate is the first member of a group of drugs which strengthens bone. Alendronate is used to reduce hypercalcemia in tumor-induced bone disease, to treat corticosteroid-induced osteoporosis and Paget's disease, and to prevent osteoporosis in postmenopausal women.
    Mechanism of action The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
    Route of administration Oral
    Categories
    • Antihypocalcemic Agents
    • Bisphosphonates
    • Antiresorptives
    • Bone Density Conservation Agents
    ATC-Code M05BA04
    AHFS-Code 92:00.00
    CAS number 66376-36-1
    Targets
    Name Sequence search Pharmacological action Actions
    Farnesyl pyrophosphate synthetase   Search  yes inhibitor
    Tyrosine-protein phosphatase non-receptor type 4   Search  unknown inhibitor
    Receptor-type tyrosine-protein phosphatase S   Search  unknown inhibitor
    Receptor-type tyrosine-protein phosphatase epsilon   Search  unknown inhibitor
    V-type proton ATPase catalytic subunit A   Search  unknown inhibitor
     
Ligand Image